AHG Akso Health Group Annual reports only
Services-Business Services, NEC · Nasdaq · SEC CIK 1702318 · Fiscal year ends 03/31
Financial factors as of 2026-03-31 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-6.4%
TTM net income YoY86.2%
TTM EPS YoY-93.8%
Revenue 3-yr CAGR1.6%
Net income 3-yr CAGR—
Margins
Gross margin-0.1%
Operating margin-149.7%
Net margin-135.0%
FCF margin-92.5%
EBITDA margin-132.5%
Returns
ROE-9.8%
ROA-9.2%
ROIC (approx.)-16.1%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets4.6%
Debt / equity0.00x
Current ratio21.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-2.9%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $13.83M | $14.78M | $2.41M | $13.18M | $6.00M |
| Cost of revenue | $13.84M | $15.06M | $2.29M | $11.91M | $5.39M |
| Gross profit | -$11,315 | -$281,526 | $122,132 | $1.27M | $605,134 |
| R&D expense | — | — | — | — | $421,186 |
| SG&A expense | $3.99M | $3.64M | $8.59M | $15.53M | $2.67M |
| Operating income | -$20.70M | -$166.30M | -$8.64M | -$14.27M | -$3.26M |
| Interest expense | — | — | — | — | $804,138 |
| Pretax income | -$20.70M | -$166.27M | -$9.09M | -$13.07M | -$4.01M |
| Income tax | -$1.99M | -$30.80M | $24,988 | $17,549 | $92,816 |
| Net income | -$18.67M | -$134.98M | -$9.46M | -$1.36M | -$16.85M |
| EBITDA | -$18.33M | -$164.15M | — | — | -$3.24M |
| EPS (basic) | 0.01 | 0.16 | 0.07 | -0.02 | -0.28 |
| EPS (diluted) | 0.01 | 0.16 | 0.07 | -0.02 | -0.28 |
| Weighted avg. shares (diluted) | 2.17B | 855.29M | 141.52M | 68.60M | 59.61M |
| Banking | |||||
| Provision for credit losses | — | — | — | — | $5.56M |
| Balance sheet | |||||
| Cash & equivalents | $170,572 | $176.23M | $85.17M | $9.19M | $21.93M |
| Receivables | $1.28M | $954,200 | — | $7.70M | — |
| Inventory | $200,135 | $190,242 | $191,201 | $1.69M | $7.80M |
| Current assets | $189.55M | $196.12M | $142.02M | $20.46M | $62.81M |
| PP&E, net | $12,015 | $16,148 | — | — | $55,433 |
| Goodwill | — | $10.83M | — | — | — |
| Intangibles | $58,319 | $7.88M | — | — | — |
| Total assets | $189.63M | $214.95M | $142.02M | $20.46M | $62.81M |
| Current liabilities | $8.71M | $13.81M | $3.59M | $11.62M | $50.52M |
| Total liabilities | $8.71M | $15.80M | $3.59M | $11.62M | $50.52M |
| Shareholders' equity | $180.93M | $199.12M | $138.37M | $8.73M | $12.28M |
| Shares outstanding | — | 1.66B | 437.17M | 68.60M | 68.60M |
| Cash flow statement | |||||
| Operating cash flow | -$12.79M | $1.18M | $1.35M | -$3.25M | -$8.63M |
| Capital expenditure | $1,638 | $154,460 | — | — | $4,861 |
| Free cash flow | -$12.79M | $1.02M | — | — | -$8.63M |
| Investing cash flow | -$163.46M | -$105.91M | -$54.72M | $18.47M | -$19.96M |
| Financing cash flow | $350,000 | $195.88M | $131.65M | -$27.51M | $34.78M |
| Depreciation & amortization | $2.37M | $2.15M | — | — | $18,390 |
| Stock-based compensation | — | — | — | — | $391,625 |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.